

Fall Group Meeting

# Chicago Specials

SEPTEMBER 18-20, 2025

Genitourinary Committee



# Genitourinary Committee

## Leadership

Chair: ..... Seth P. Lerner, MD  
 Vice-Chair: ..... Daniel P. Petrylak, MD  
 Chair Emeritus: ..... Ian M. Thompson, Jr., MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Cathy M. Tangen, DrPH  
 ..... Melissa Plets, MS  
 ..... Sam Callis, MS  
 ..... Gabby Lopez, MS  
 ..... Sara Threlkel, BS

## Scientific Leadership

Translational Medicine: ..... Joshua J. Meeks, MD, PhD (GU Chair)  
 ..... Roger Li, MD (Bladder)  
 ..... Amir Goldkorn, MD (Prostate)  
 ..... Sumanta “Monty” K. Pal, MD (Renal)  
 ..... David McConkey, PhD (Advisor)  
 Radiation Oncology: ..... James B. Yu, MD  
 ..... Daniel A. Hamstra, MD  
 Imaging: ..... Evan Y. Yu, MD  
 ..... Hiram Shaish, MD  
 ..... John D. Hazle, PhD

Theranostics: ..... Andrei Iagaru, MD  
 ..... Yun Rose Li, MD, PhD

Immunotherapeutics: ..... Shuchi Gulati, MD (Medical Onc)  
 ..... Robert Svatek, MD (Urologic Onc)

Pathology: ..... M. Scott Lucia, MD  
 Surgery: ..... Kelly L. Stratton, MD

Early Therapeutics: ..... Parminder Singh, MD

Bladder Organ Site Chairs: ..... Siamak Daneshmand, MD (Localized)  
 ..... Thomas W. Flaig, MD (Advanced)

Prostate Organ Site Chairs: ..... Daniel W. Lin, MD (Localized)  
 ..... Tanya B. Dorff, MD (Advanced)

Renal Organ Site Chairs: ..... Brian Shuch, MD (Localized)  
 ..... Ulka N. Vaishampayan, MD (Advanced)

## Designates

Cancer Control: ..... Clara Hwang, MD  
 ..... Sarah P. Psutka, MD, MSC

Accrual Champion: ..... Jessica D. McDermott, MD  
 International Liaison: ..... Sumanta “Monty” K. Pal, MD

NCORP: ..... Scott Edward Delacroix, Jr., MD  
 ..... Helen Heng-Shan Moon, MD

Veterans Affairs: ..... Michael M. Goodman, MD  
 ..... Aihua Edward Yen, MD

Data Coordinators: ..... Laura Wells, BA  
 ..... Tonya Johnson, BS  
 ..... Michele Counts, BS

## Oncology Research Professionals:

CRA: ..... Abigail L. Cornette, MS  
 Nurse: ..... Gary Lee Duvall, RN

Patient Advocates: ..... Darrell Nakagawa (Bladder)  
 ..... Joël R. Pointon, MPH (Prostate)

..... Laura B. Esfeller, MA (Renal)  
 ..... Rick Bangs, MBA (Emeritus)

Pharmaceutical Science: ..... TBD

Senior Protocol Project Manager: ..... Megan Keim

Clinical Trials Program Manager: ..... Sarah Cantu

## Time/Location

Saturday, September 20, 2025 9:15 a.m. - 11:15 a.m.

Room: Regency A (Ballroom Level, West Tower)

## Agenda

9:15 - 9:30 am: Chair's Welcome and Opening Remarks - Seth Lerner

9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka

9:55 - 11:15 am: Review of open approved trials - all organ site chairs

Prostate – Dan Lin and Tanya Dorff

Renal – Brian Shuch and Ulka Vaishampayan

Bladder – Sia Daneshmand and Tom Flaig

## Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

## Active Studies

**S1600**, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

**S1823**, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/20 GU Champions: Thomas Frye & Anishka D’Souza

**S1931 (Companion Study)**: Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.



# Genitourinary Committee

**S1937 (Companion Study):** Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

## Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

### Priority Study

**S2210,** "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23.

### Active Studies

**S2312,** "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24.

**S1802,** "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

**CTSU/A031102,** "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

**CTSU/EA8171,** "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

**CTSU/EA8184,** "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

**CTSU/NRG-GU002,** "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

**CTSU/NRG-GU008,** "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE\*) \*Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

**CTSU/NRG-GU009,** "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT\*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

### Closed Studies

**S1216,** "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25.

**CTSU/NRG-GU005,** "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

**CTSU/NRG-GU006,** "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

**CTSU/RT0G-0924,** "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

**CTSU/NRG-GU007,** "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR\*) \*Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/22.



# Genitourinary Committee

**CTSU/EA8153**, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

**CTSU/AGCT1531**, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

## Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

### Priority Study

**S1931**, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

### Concepts in Development

**S2419**, “Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial].” Drs. P. Barata and U. Vaishampayan. Submitted to CTEP for initial review on 6/20/25.

### Active Studies

**S2200**, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. Activated 9/19/22.

**CTSU/AREN1721**, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

**CTSU/A031704**, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

**CTSU/A031801**, “A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical).” Dr. M. Parikh. Activated: 12/13/19.

**CTSU/A031901**, “Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial.” Dr. D. Vaena. Activated: 12/10/20.

### Closed Studies

**S1500**, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).” Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

**S0931**, “EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.” Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

**CTSU/E2810**, “Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.” Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

**CTSU/A031501**, “Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.” Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

**CTSU/EA8143**, “A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC).” Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

## Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

### Priority Study

**S1937**, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

### Concepts in Development

**S2427**, “Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer



# Genitourinary Committee

(BRIGHT).” Dr. L. Ballas. PRC call occurred 1/29/25. Submitted to CTEP 3/5/25, Approval on hold received 6/26/25. CIRB review scheduled for 7/17/25.

## Active Studies

**S1806**, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 submitted to CTEP on 5/29, pending review.

**CTSU/A031701**, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

**CTSU/A031803**, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

**CTSU/EA8185**, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

**CTSU/EA8192**, “A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

## Closed Studies

**S1011**, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

**S1602**, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/20.

**S1605**, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

**S2011**, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23.

## Diverse Studies of Interest

**S1609**, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

**CTSU/A031702**, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

**CTSU/EAY 131**, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

**CTSU/EA8134**, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

## Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

## Published/Accepted Manuscripts

**S1314** Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression. Bai Z, Brendel M, Osman M, Tangen C, Flaig T, Thompson I, Plets M, Lucia MS, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. NPJ Digital Medicine Mar 22;8(1):174, 2025. <https://pubmed.ncbi.nlm.nih.gov/40121304/>



# Genitourinary Committee

**S1314** Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning framework. Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Lucia MS, Theodorescu D, Guftason D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. *Digital Medicine* Mar 22;8(1):174, 2025.

<https://pubmed.ncbi.nlm.nih.gov/40121304/>

**S1605** Urine tumor DNA detection predicts response to atezolizumab in BCG-unresponsive non-muscle-invasive bladder cancer. St-Laurent M, Singh P, McConkey D, Lucia MS, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzarella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. *European Urology* May 21:S0302-2838(25)00217-9, 2025.

<https://pubmed.ncbi.nlm.nih.gov/40404526/>

**C90601** Relationship among DNA damage response gene alterations, molecular subtypes, and survival outcomes in patients with metastatic bladder cancer treated on CALGB 90601. Iyer G, Choi W, Luo B, Carvalho F, Hanlon T, Reis H, Guerico B, Fong M, Mountain J, Feng M, Regazzi A, McCart A, Wen Y, Al-Ahmadie H, Mouw K, Van Allen E, Bellmunt J, Dreicer R, Flaig T, Halabi S, McConkey D, Rosenberg J. *JCO Precision Oncology* Jul;9:e2400938 2025. <https://pubmed.ncbi.nlm.nih.gov/40591902/>

## Submitted Manuscripts

**S1216** Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Submitted, 2025.



## Genitourinary Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	<i>S1802</i>	<i>S1806</i>	<i>S1931</i>	<i>S1937</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>A021804</i>	<i>A031701</i>	<i>A031702</i>	<i>A031704</i>
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	-	1	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	5	8	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	10	-	-
Cancer Research Consortium of West Michigan NCORP	2	8	1	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-	-	1
Cancer Research of Wisconsin and N Michigan Consortium	2	6	-	1	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	1	1	1	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	11	4	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	-	3	-	6	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	5	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	2	-	-	-	-	-	-	-	-	1
Desert Regional Medical Center	2	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	25	-	-	-	-	3	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	5	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	73	2	-	1	1	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	8	1	-	3	-	1	-	2	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-	-	-	-	-	3
Henry Ford Hospital	28	4	-	3	-	-	-	-	-	2	6
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	4	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	36	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Prgrm	18	-	2	-	-	-	-	-	-	-	66
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	7	-
Loyola University Medical Center	9	6	1	2	-	-	-	-	-	1	2
Medical University of S Carolina Minority Underserved NCORP	8	-	-	3	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	15	20	-	3	2	-	3	-	1	-	-
Montana Cancer Consortium NCORP	5	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	11	-	-	-	-	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	-	-	1	1	-	-	-	-	-	-	1



## Genitourinary Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	<i>S1802</i>	<i>S1806</i>	<i>S1931</i>	<i>S1937</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>A021804</i>	<i>A031701</i>	<i>A031702</i>	<i>A031704</i>
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-	1
Northwestern University LAPS	-	8	1	1	1	-	2	-	-	-	2
Ohio State University Comprehensive Cancer Center LAPS	2	3	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	1	2	1	1	1	-	1	-	5	5
Regents of the University of Michigan	2	-	27	-	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	2	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	1	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	3	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	9	-	-	-	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	14	9	2	4	-	-	-	-	10	-	3
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	6	-	2	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	5	3	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	8	3	1	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	8	-	1	15	-	-	-	-	-	5	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	7	-	-	-	-	-	-	1	-
University of Arkansas for Medical Sciences	9	-	-	-	1	-	1	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	8	6	3	-	-	-	-	-	-	-	7
University of Colorado Cancer Center LAPS	10	6	-	8	-	-	-	-	-	-	11
University of Kansas Cancer Center - MCA Rural MU NCORP	7	9	-	2	-	-	-	-	-	1	7
University of Kentucky/Markey Cancer Center	2	3	-	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	1	-	-	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	44	15	5	5	3	-	4	-	-	-	-
University of Rochester LAPS	25	-	3	-	-	-	-	-	1	3	9
University of Texas Health Science Center at San Antonio	13	-	6	-	-	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	86	-	-	-	-	-	7	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	2	3	3	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	3	2	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	6	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	14	6	-	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	6	-	3	-	-	-	-	-	-	1
ALLIANCE	116	34	8	5	2	-	4	-	-	-	-
ECOG-ACRIN	102	44	15	15	6	-	-	-	-	-	-
NRG	113	136	14	2	4	-	-	-	-	-	-
<b>Total</b>	<b>933</b>	<b>485</b>	<b>129</b>	<b>91</b>	<b>34</b>	<b>5</b>	<b>23</b>	<b>1</b>	<b>24</b>	<b>27</b>	<b>130</b>



## Genitourinary Committee

***Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study***

[illegible]



## Genitourinary Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	A031801	A031803	A032001	A032101	A032103	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008
Northwell Health NCORP	-	-	-	-	-	-	-	1	-	-	4
Northwestern University LAPS	-	-	-	1	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	7	-	15	18	-	29	-
Regents of the University of Michigan	-	-	-	12	1	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	5	2	-	1	-	-	-	-	3	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	2
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-	-	-	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	16	-	-	-	18	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	1	12	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	2	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	-	1	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-	-	2
University of Kentucky/Markey Cancer Center	-	-	-	-	1	-	-	-	2	15	-
University of Mississippi Medical Center	-	-	-	-	2	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	1	-	-	6	-	7	-
University of Rochester LAPS	-	-	-	-	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	6	-	-	-	-	13	2	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	6	-	-	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	9	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>15</b>	<b>47</b>	<b>15</b>	<b>16</b>	<b>21</b>	<b>19</b>	<b>91</b>	<b>65</b>	<b>4</b>	<b>248</b>	<b>14</b>



## Genitourinary Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	4	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-
Banner MD Anderson Cancer Center	1	3	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Cancer Research of Wisconsin and N Michigan Consortium	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	5	-	4
Georgia Cares Minority Underserved NCORP	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-
Gulf South Minority Underserved NCORP	16	6	5	2	-
Hawaii Minority Underserved NCORP	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-
Medical University of S Carolina Minority Underserved NCORP	-	1	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-



## Genitourinary Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Northwell Health NCORP	20	3	-	-	-
Northwestern University LAPS	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-
Oregon Health and Science University	-	-	6	-	-
Regents of the University of Michigan	-	1	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	3	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-
Sutter Cancer Research Consortium	6	10	1	1	-
The West Clinic - Wolf River	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-
University of Colorado Cancer Center LAPS	17	10	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	10	7	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-
University of Mississippi Medical Center	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	4	4	-	2	5
University of Rochester LAPS	-	-	-	-	-
University of Texas Health Science Center at San Antonio	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-
Virginia Mason Medical Center	4	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-
Western States Cancer Research NCORP	2	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
<b>Total</b>	<b>87</b>	<b>63</b>	<b>18</b>	<b>7</b>	<b>9</b>



